Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 156-160

  Thunnissen, F B ^a,b   Prinsen, C ^b   Hol, B ^b   Van der Drift, M ^c   Vesin, A ^d   Brambilla, C ^e   Montuenga, L ^f   Field, J K ^g  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d INSERM   (France)

^e INSTITUT ALBERT BONNIOT   (France)

^f UNIVERSITY OF NAVARRA   (Spain)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Carcinogenesis; KRAS; Lung cancer; Smoking

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SMOKING; SMOKING CESSATION; TIME FACTORS;

EID: 84855439033     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.07.013     Document Type: Article

References (37)

1. Rodenhuis S., Slebos R.J., Boot A.J., Evers S.G., Mooi W.J., Wagenaar S.S., et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988, 48:5738-5741.
2. Liaw Y.P., Ting T.F., Ho K.K., Yang C.F. Cell type specificity of lung cancer associated with air pollution. Sci Total Environ 2008, 395:23-27.
3. Husgafvel-Pursiainen K., Hackman P., Ridanpaa M., Anttila S., Karjalainen A., Partanen T., et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 1993, 53:250-256.
4. Sakuma Y., Matsukuma S., Yoshihara M., Nakamura Y., Noda K., Nakayama H., et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007, 128:100-108.
5. Reynolds S.H., Anna C.K., Brown K.C., Wiest J.S., Beattie E.J., Pero R.W., et al. Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci USA 1991, 88:1085-1089.
6. Li Z.H., Zheng J., Weiss L.M., Shibata D. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994, 144:303-309.
7. Cooper C.A., Carby F.A., Bubb V.J., Lamb D., Kerr K.M., Wyllie A.H. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol 1997, 181:401-404.
8. Westra W.H., Slebos R.J., Offerhaus G.J., Goodman S.N., Evers S.G., Kensler T.W., et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993, 72:432-438.
9. Field J.K., Liloglou T., Niaz A., Bryan J., Gosney J.R., Giles T., et al. EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. Eur Respir J 2009, 34:1477-1486.
10. Somers V.A., Moerkerk P.T., Murtagh J.J., Thunnissen F.B. A rapid, reliable method for detection of known point mutations: point-EXACCT. Nucleic Acids Res 1994, 22:4840-4841.
11. Somers V.A., Pietersen A.M., Theunissen P.H., Thunnissen F.B. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. J Clin Oncol 1998, 16:3061-3068.
12. Somers V.A., Leimbach D.A., Theunissen P.H., Murtagh J.J., Holloway B., Ambergen A.W., et al. Validation of the Point-EXACCT method in non-small cell lung carcinomas. Clin Chem 1998, 44:1404-1409.
13. Klaassen C.H., Prinsen C.F., de Valk H.A., Horrevorts A.M., Jeunink M.A., Thunnissen F.B. DNA microarray format for detection and subtyping of human papillomavirus. J Clin Microbiol 2004, 42:2152-2160.
14. Prinsen C.F., Fles R., Wijnen-Dubbers C.W., de Valk H.A., Klaassen C.H., Mravunac M., et al. Baseline human papillomavirus status of women with abnormal smears in cervical screening: a 5-year follow-up study in The Netherlands. BJOG 2007, 114:951-957.
15. Prinsen C.F., Klaassen C.H., Thunnissen F.B. Microarray as a model for quantitative visualization chemistry. Appl Immunohistochem Mol Morphol 2003, 11:168-173.
16. Ichikawa T., Yano Y., Uchida M., Otani S., Hagiwara K., Yano T. The activation of K-ras gene at an early stage of lung tumorigenesis in mice. Cancer Lett 1996, 107:165-170.
17. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
18. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008, 105:3903-3908.
19. Stegelmeier B.L., Gillett N.A., Rebar A.H., Kelly G. The molecular progression of plutonium-239-induced rat lung carcinogenesis: Ki-ras expression and activation. Mol Carcinog 1991, 4:43-51.
20. Yano T., Yuasa M., Murakami A., Ichikawa T., Hagiwara K. The detection of chemically initiated cells having the mutation of K-ras gene at an early stage of lung carcinogenesis in mice. Anal Biochem 1997, 244:187-189.
21. You M., Candrian U., Maronpot R.R., Stoner G.D., Anderson M.W. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 1989, 86:3070-3074.
22. Riely G.J., Kris M.G., Rosenbaum D., Marks J., Li A., Chitale D.A., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14:5731-5734.
23. Rustemeier K., Stabbert R., Haussmann H.J., Roemer E., Carmines E.L. Evaluation of the potential effects of ingredients added to cigarettes. Part 2. Chemical composition of mainstream smoke. Food Chem Toxicol 2002, 40:93-104.
24. Sills R.C., Hong H.L., Greenwell A., Herbert R.A., Boorman G.A., Devereux T.R. Increased frequency of K-ras mutations in lung neoplasms from female B6C3F1 mice exposed to ozone for 24 or 30 months. Carcinogenesis 1995, 16:1623-1628.
25. Belinsky S.A., Devereux T.R., Maronpot R.R., Stoner G.D., Anderson M.W. Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res 1989, 49:5305-5311.
26. Vahakangas K.H., Samet J.M., Metcalf R.A., Welsh J.A., Bennett W.P., Lane D.P., et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992, 339:576-580.
27. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
28. David S.S., O'Shea V.L., Kundu S. Base-excision repair of oxidative DNA damage. Nature 2007, 447:941-950.
29. Tarafa G., Tuck D., Ladner D., Topazian M., Brand R., Deters C., et al. Mutational load distribution analysis yields metrics reflecting genetic instability during pancreatic carcinogenesis. Proc Natl Acad Sci USA 2008, 105:4306-4311.
30. Giangreco A., Arwert E.N., Rosewell I.R., Snyder J., Watt F.M., Stripp B.R. Stem cells are dispensable for lung homeostasis but restore airways after injury. Proc Natl Acad Sci USA 2009, 106:9286-9291.
31. Urban T., Ricci S., Lacave R., Antoine M., Kambouchner M., Capron F. Bernaudin JF. Codon 12 Ki-ras mutation in non-small-cell lung cancer: comparative evaluation in tumoural and non-tumoural lung. Br J Cancer 1996, 74:1051-1055.
32. Keohavong P., Zhu D., Whiteside T.L., Swalsky P., Bakker A., Elder E.M., et al. Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem 1997, 247:394-403.
33. Ohshima S., Shimizu Y., Takahama M. Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung. Virchows Arch 1994, 424:129-134.
34. Sakamoto H., Shimizu J., Horio Y., Ueda R., Takahashi T., Mitsudomi T., et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 2007, 212:287-294.
35. Hasegawa M., Sone S., Takashima S., Li F., Yang Z.G., Maruyama Y., et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000, 73:1252-1259.
36. Thunnissen F.B., Schuurbiers O.C., den Bakker M.A. A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology 2006, 48:779-786.
37. Winer-Muram H.T., Jennings S.G., Tarver R.D., Aisen A.M., Tann M., Conces D.J., et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002, 223:798-805.